SE443716B - Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor - Google Patents
Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitorInfo
- Publication number
- SE443716B SE443716B SE7805707A SE7805707A SE443716B SE 443716 B SE443716 B SE 443716B SE 7805707 A SE7805707 A SE 7805707A SE 7805707 A SE7805707 A SE 7805707A SE 443716 B SE443716 B SE 443716B
- Authority
- SE
- Sweden
- Prior art keywords
- pyrazolo
- pyridine
- ethyl
- pharmaceutically acceptable
- phosphodiesterase inhibitor
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 230000002401 inhibitory effect Effects 0.000 title claims description 3
- 239000008280 blood Substances 0.000 title description 18
- 210000004369 blood Anatomy 0.000 title description 18
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title description 12
- 239000003112 inhibitor Substances 0.000 title description 3
- 238000005204 segregation Methods 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 36
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 31
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- 229960000278 theophylline Drugs 0.000 claims description 12
- 229960002768 dipyridamole Drugs 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 10
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical group C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 9
- 102000016736 Cyclin Human genes 0.000 claims description 7
- 108050006400 Cyclin Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical group O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical group C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical group [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- ZOWYFYXTIWQBEP-UHFFFAOYSA-N 1-[(3,4-diethoxyphenyl)methyl]-6,7-diethoxyisoquinoline Chemical compound C1=C(OCC)C(OCC)=CC=C1CC1=NC=CC2=CC(OCC)=C(OCC)C=C12 ZOWYFYXTIWQBEP-UHFFFAOYSA-N 0.000 claims description 2
- PHOQGTWDVPGPJO-UHFFFAOYSA-N 2-(4-chloro-1-ethyl-3-methylpyrazolo[3,4-b]pyridin-5-yl)acetonitrile Chemical compound N#CCC1=CN=C2N(CC)N=C(C)C2=C1Cl PHOQGTWDVPGPJO-UHFFFAOYSA-N 0.000 claims description 2
- JYARBGGPLKDNRV-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC(CN(C)C)C(=O)C2=CC(OC)=CC=C21 JYARBGGPLKDNRV-UHFFFAOYSA-N 0.000 claims description 2
- ZQEAOLDJTCZWIH-UHFFFAOYSA-N 2-methyl-6-phenyl-4-piperidin-1-ylpyrazolo[3,4-b]pyridine Chemical compound N=1C2=NN(C)C=C2C(N2CCCCC2)=CC=1C1=CC=CC=C1 ZQEAOLDJTCZWIH-UHFFFAOYSA-N 0.000 claims description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003556 aminophylline Drugs 0.000 claims description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 125000006309 butyl amino group Chemical group 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- KUKBQDRNIFJRLX-UHFFFAOYSA-N ethyl 1-ethyl-3-methyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=C(C)C2=C1NN=C(C)C KUKBQDRNIFJRLX-UHFFFAOYSA-N 0.000 claims description 2
- 150000002537 isoquinolines Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960001789 papaverine Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- RDEGFHUPHVYMOD-UHFFFAOYSA-N 11-oxa-2,4,5-triazatricyclo[7.3.0.03,7]dodeca-1(12),2,4,6,8-pentaen-10-one Chemical compound N1=C2N=NC=C2C=C2C(=O)OC=C21 RDEGFHUPHVYMOD-UHFFFAOYSA-N 0.000 claims 1
- FWFVOHOJYQEBDV-UHFFFAOYSA-N 11h-pyrido[4,3-b][1,5]benzodiazepine Chemical compound C1=NC2=CC=CC=C2NC2=CC=NC=C21 FWFVOHOJYQEBDV-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 claims 1
- ISFDRJXUWTUUMS-UHFFFAOYSA-N n'-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)ethane-1,2-diamine Chemical compound C=12SC=CC2=NC(NCCN)=NC=1N1CCOCC1 ISFDRJXUWTUUMS-UHFFFAOYSA-N 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 52
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 230000002744 anti-aggregatory effect Effects 0.000 description 13
- 230000000304 vasodilatating effect Effects 0.000 description 12
- 229960001123 epoprostenol Drugs 0.000 description 11
- 210000002435 tendon Anatomy 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QCOZYUGXYJSINC-UHFFFAOYSA-N 1,3,7-trimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CN1C(=O)N(C)C(=O)C2=C1N=CN2C QCOZYUGXYJSINC-UHFFFAOYSA-N 0.000 description 1
- SZXKGHSWPXMILO-UHFFFAOYSA-N 10-chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo-[4',3':5,6]pyrido[4,3-b][1,5]benzodiazepin-6(3h)-one Chemical compound CN1C(=O)C2=CN=C3N(CC)N=CC3=C2N(C)C2=CC(Cl)=CC=C21 SZXKGHSWPXMILO-UHFFFAOYSA-N 0.000 description 1
- RZPFVRFSYMUDJO-UHFFFAOYSA-N 2h-naphthalen-1-one Chemical class C1=CC=C2C(=O)CC=CC2=C1 RZPFVRFSYMUDJO-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- VDYSTDTZDXTLCV-UHFFFAOYSA-N 4-(2,4-dimorpholin-4-ylpyrimido[5,4-d]pyrimidin-6-yl)morpholine Chemical compound C1COCCN1C1=NC=C(N=C(N=C2N3CCOCC3)N3CCOCC3)C2=N1 VDYSTDTZDXTLCV-UHFFFAOYSA-N 0.000 description 1
- CGJSSCMIRBKUPH-UHFFFAOYSA-N 4-(butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5h-furo-[3,4-e]pyrazolo[3,4-b]pyridin-5-one Chemical compound CCCCNC1=C2C(=O)OC(O)C2=NC2=C1C=NN2CC CGJSSCMIRBKUPH-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UOBSYEOJKWEKCT-UHFFFAOYSA-N ethyl 4-(butylamino)-1h-pyrazolo[3,4-b]pyridine-6-carboxylate Chemical compound CCCCNC1=CC(C(=O)OCC)=NC2=C1C=NN2 UOBSYEOJKWEKCT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79900777A | 1977-05-20 | 1977-05-20 | |
| GB3526177 | 1977-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7805707L SE7805707L (sv) | 1978-11-21 |
| SE443716B true SE443716B (sv) | 1986-03-10 |
Family
ID=26262642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7805707A SE443716B (sv) | 1977-05-20 | 1978-05-18 | Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS542335A (enrdf_load_stackoverflow) |
| CH (1) | CH643458A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2821737A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2390964A1 (enrdf_load_stackoverflow) |
| HU (1) | HU180548B (enrdf_load_stackoverflow) |
| IT (1) | IT1105506B (enrdf_load_stackoverflow) |
| NL (1) | NL7805402A (enrdf_load_stackoverflow) |
| SE (1) | SE443716B (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA787353B (en) * | 1978-05-17 | 1980-08-27 | Wellcome Found | Pharmaceutical formulations |
| DE3526362A1 (de) * | 1985-07-19 | 1987-01-22 | Schering Ag | Prostacycline, ihre analoga oder prostaglandine und thromboxanantagonisten zur behandlung von thrombotischen und thromboembolischen krankheitsbildern |
| DE3874440T2 (de) * | 1987-07-14 | 1993-01-28 | Sankyo Co | Zusammensetzung zur herstellung von antithrombotischen medizinischen erzeugnissen. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2235678A1 (en) * | 1973-07-02 | 1975-01-31 | Merck & Co Inc | Topical antipsoriasis agents - contg. prostaglandin E1 or E2 |
-
1978
- 1978-05-18 JP JP5946078A patent/JPS542335A/ja active Pending
- 1978-05-18 DE DE19782821737 patent/DE2821737A1/de active Granted
- 1978-05-18 SE SE7805707A patent/SE443716B/sv not_active IP Right Cessation
- 1978-05-18 HU HU78WE576A patent/HU180548B/hu unknown
- 1978-05-18 NL NL7805402A patent/NL7805402A/xx not_active Application Discontinuation
- 1978-05-18 CH CH541678A patent/CH643458A5/de not_active IP Right Cessation
- 1978-05-18 FR FR7814729A patent/FR2390964A1/fr active Granted
- 1978-05-22 IT IT49485/78A patent/IT1105506B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| NL7805402A (nl) | 1978-11-22 |
| FR2390964B1 (enrdf_load_stackoverflow) | 1980-07-11 |
| IT1105506B (it) | 1985-11-04 |
| IT7849485A0 (it) | 1978-05-22 |
| SE7805707L (sv) | 1978-11-21 |
| DE2821737A1 (de) | 1978-11-30 |
| FR2390964A1 (fr) | 1978-12-15 |
| JPS542335A (en) | 1979-01-09 |
| DE2821737C2 (enrdf_load_stackoverflow) | 1988-05-19 |
| HU180548B (en) | 1983-03-28 |
| CH643458A5 (en) | 1984-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1461039B1 (en) | Pharmaceutical compositions comprising cilostazol and an adenosine uptake inhibitor | |
| JP6014695B2 (ja) | 癌および他の疾患または障害の治療のための医薬組成物 | |
| EP1097709A2 (en) | Use of corticotropin releasing factor antagonists for treating syndrome X | |
| Casals‐Stenzel et al. | Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity | |
| KR101176110B1 (ko) | 문맥성 고혈압의 예방 및/또는 치료 | |
| US4337254A (en) | Pharmaceutical compositions | |
| SE443716B (sv) | Sett att framstella en farmaceutisk beredning for inhibering av blodplettsaggregation innehallande prostacyklin eller dihydroprostacyklin och en fosfodiesterasinhibitor | |
| KR101603279B1 (ko) | 프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| EP0667349A1 (en) | Depression remedy | |
| KR20190085946A (ko) | 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신 손상 예방 또는 치료용 약학적 조성물 | |
| GB1601034A (en) | Pharmaceutical compositions | |
| US11241441B2 (en) | Formulations of lixivaptan for the treatment of polycystic disease | |
| US3987173A (en) | Pharmaceutical preparations comprising vincamine alkaloids and dihydroergocristine | |
| ES2260061T3 (es) | Composiciones farmaceuticas para trastornos relacionados con la alimentacion. | |
| EP0011828A1 (en) | Pharmaceutical combinations including hydantoin derivatives, pharmaceutical formulations containing the combinations and methods of making the formulations | |
| EP0338010B1 (en) | Pharmaceutical compositions for treatment of hyperproliferate skin disease | |
| JPH02142728A (ja) | 抗アテローム性動脈硬化症剤及び抗過コレステリン血症剤としてのピラゾロピリジン誘導体 | |
| WO2018144791A1 (en) | Combination of vps34 inhibitors and mtor inhibitors | |
| HK40054977A (en) | Novel quinazoline egfr inhibitors | |
| AU4281993A (en) | Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith | |
| MXPA99010735A (en) | THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES | |
| HU193280B (en) | Process for preparing novel hidantane derivatives and compositions comprising the same as active substance | |
| RU97116586A (ru) | 6-арил-пиразоло[3,4-d]пиримидин-4-оны, составы на их основе и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7805707-2 Effective date: 19890525 Format of ref document f/p: F |